Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia

References

• Roth T. New developments for treating sleep disorders. J Clin Psychiatry 2001;62(Suppl 10):3–4
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999;22\(Suppl 2):S347–S353
   Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111
   PubMed Web of Science ®Google Scholar
• Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42:225–32
   Google Scholar
• Rosa RR, Bonnet MH. Reported chronic insomnia is independent of poor sleep as measured by electroencephalography. Psychosom Med 2000;62:474–82
   PubMed Web of Science ®Google Scholar
• Stepanski E, Zorick F, Roehrs T, et al. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 1988;11:54–60
   PubMed Web of Science ®Google Scholar
• Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening – temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551–4
   PubMed Web of Science ®Google Scholar
• Scharf MB, Roth PB, Dominguez RA, et al. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol 1990; 30:461–7
   PubMed Web of Science ®Google Scholar
• Kripke DF, Hauri P, Ancoli-Israel S, et al. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990;10:32S–43S
   Google Scholar
• Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;16:146–57
   PubMed Web of Science ®Google Scholar
• Scharf MB, Fletcher K, Graham JP. Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry 1988;49:134–7
   Google Scholar
• Roth T, Hartse KM, Saab PG, et al. The effects of flurazepam, lorazepam, and triazolam on sleep and memory. Psychopharmacology (Berl) 1980;70:231–7
   PubMed Web of Science ®Google Scholar
• Judd LL, Ellinwood E, McAdams LA. Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990;10:56S–67S
   Google Scholar
• Johnson LC, Chernik DA, Hauri P. A multicenter 14-day study of flurazepam and midazolam in chronic insomniacs: general discussion and conclusions. J Clin Psychopharmacol 1990;10:76S–90S
   Google Scholar
• Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116–25
   PubMed Web of Science ®Google Scholar
• Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharm 1998;13:191–8
   Web of Science ®Google Scholar
• Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002;17:9–17
   PubMed Web of Science ®Google Scholar
• Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192–9
   PubMed Web of Science ®Google Scholar
• Hedner J, Yaeche R, Emilien G, et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15:704–12
   PubMed Web of Science ®Google Scholar
• Elie R, Ruther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic [Zaleplon Clinical Study Group]. J Clin Psychiatry 1999;60:536–44
   PubMed Web of Science ®Google Scholar
• Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41–9
   PubMed Web of Science ®Google Scholar
• Davies M, Newell JG, Derry JM, et al. Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors. Mol Pharmacol 2000;58:756–62
   PubMed Web of Science ®Google Scholar
• Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol 1999;13:S11–S20
   PubMed Web of Science ®Google Scholar
• Leese P, Maier G, Vaickus L, et al. Esopiclone: pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. Sleep 2002;25:A45
   Web of Science ®Google Scholar
• Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990;19:53–61
   PubMed Web of Science ®Google Scholar
• Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996;19:333–40
   PubMed Web of Science ®Google Scholar
• Ponciano E, Freitas F, Camara J, et al. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990;5(Suppl 2):69–77
   PubMed Web of Science ®Google Scholar
• Gringras M, Beaumont G, Ankier SI. A comparison of the hypnotic activity of loprazolam, temazepam and placebo in general practice. J Int Med Res 1984;12:10–6
   Google Scholar
• Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52:77–83
   PubMed Web of Science ®Google Scholar
• Kaynak H, Kaynak D, Gozukirmizi E, et al. The effects of trazodone on sleep in patients treated with stimulant anti-depressants. Sleep Med 2004;5:15–20
   PubMed Web of Science ®Google Scholar
• Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990;5:191–4
   PubMed Web of Science ®Google Scholar
• Blazer DG, Hays JC, Foley DJ. Sleep complaints in older adults: a racial comparison. J Gerontology: Med Sci 1995;50A:M280–M284
   Google Scholar
• Jean-Louis G, Magai CM, Cohen CI, et al. Ethnic differences in self-reported sleep problems in older adults. Sleep 2001;17:703–10
   Google Scholar
• National Sleep Foundation. Sleep in America poll. Washington DC: Author; 2002
   Google Scholar
• Walsh JK, Fry J, Erwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 1998;16:347–54
   Web of Science ®Google Scholar
• Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989;9:161–72
   Google Scholar
• Hajak G, Clarenbach P, Fischer W, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 1998;248:148–56
   PubMed Web of Science ®Google Scholar
• Hegelbach-Feller DA, Tschopp JM, Christeller S, et al. Comparison of the short-acting benzodiazepines midazolam and triazolam with placebo. Arzneimittelforschung 1988;38:387–92
   Google Scholar
• Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150–61
   Google Scholar
• Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127–36
   Google Scholar
• Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793–9
   PubMed Web of Science ®Google Scholar